<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00384514</url>
  </required_header>
  <id_info>
    <org_study_id>TV-001</org_study_id>
    <nct_id>NCT00384514</nct_id>
  </id_info>
  <brief_title>EPC by Intracoronary Injection in Patients With Chronic Stable Angina</brief_title>
  <official_title>A Study for Testing Safety and Efficacy of the Administration of Blood-Borne Autologous Endothelial Progenitor Cells to Alleviate Anginal Symptoms and Myocardial Ischemia in Patients With Severe Anginal Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TheraVitae Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>TheraVitae Ltd.</source>
  <brief_summary>
    <textblock>
      Study title:A Study for Testing Safety and Efficacy of the administration of Blood-Borne&#xD;
      Autologous Endothelial Progenitor Cells to Alleviate Anginal Symptoms and Myocardial Ischemia&#xD;
      in Patients with Severe Anginal Syndrome&#xD;
&#xD;
      Principle Investigator: Assoc. Prof. Damras,Tresukosol,M.D.,Head of Cardiac Catherlization&#xD;
      unit,Division of Cardiology,Department of Medicine,Faculty of Medicine Siriraj&#xD;
      Hospital,Mahidol University&#xD;
&#xD;
      Study objective : To determine the safety and efficacy of intracoronary injection of&#xD;
      blood-borne autologous EPCs in relieving symptoms of angina pectoris in symptomatic patients&#xD;
      treated with maximal medical therapy with an occluded coronary artery supplying ischemic&#xD;
      myocardium Study Design : Phase II, a single center,a non-randomized,open-label trial,&#xD;
&#xD;
      Study population :&#xD;
&#xD;
      Total expected no. of patients : 24&#xD;
&#xD;
      main selection criteria :&#xD;
&#xD;
        -  Patients with chronic stable angina on maximal medical therapy and an occluded coronary&#xD;
           artery supplying an ischemic viable myocardial region as shown on Sesta-mibi scan. On&#xD;
           coronary angiography,the occluded coronary artery must have a patent proximal segment of&#xD;
           at least 30 mm with at least one side branch to enable the injection of the EPC if the&#xD;
           vessel remains occluded despite the attempted angioplasty efforts.&#xD;
&#xD;
        -  Age 18-80 years&#xD;
&#xD;
        -  Ejection fraction &gt;35 % on Sesta-mibi scan&#xD;
&#xD;
        -  Sestamibi scan (myocardial perfusion) during exercise or dipyridamole,demonstrating&#xD;
           regional reversible ischemia in an area relating to the occluded coronary artery.&#xD;
&#xD;
      Investigational Product : At D-8 250 ml of blood drawn from the patients for production of&#xD;
      autologous EPCs or ACPs (VescellTM), On D0 ,at least 1.5 million EPCs with viability &gt;75 %&#xD;
      suspended in 6 ml sterile cell culture medium will be injected to the same patients by&#xD;
      intracoronary artery.&#xD;
&#xD;
      The study consists of 4 periods:Screening ( D-14to-9&amp;D-8,Treatment(D0),Acute Safety follow-up&#xD;
      (D1&amp;D2),Chronic follow-up (D30,D90&amp;D180)period ,total follow-up of each case is 6 months.&#xD;
&#xD;
      Evaluation criteria :&#xD;
&#xD;
      Safety : no.&amp; duration of adverse event &amp; serious adverse event&#xD;
&#xD;
      Efficacy :&#xD;
&#xD;
        -  change from baseline to 1,3,6 months of CCS, 6-minute walking test&#xD;
&#xD;
        -  change from baseline to 3 &amp; 6 months of Sesta-mibi scan&#xD;
&#xD;
        -  change from baseline to 3 &amp; 6 months of symptom-limited exercise time,exercise-induced&#xD;
           ischemia &amp; METs on Sesta-mibi scan Duration of study: July 2004-December 2006&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2004</start_date>
  <completion_date>September 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety : no.&amp; duration of adverse event &amp; serious adverse event</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy :change from baseline to 1,3,6 months of CCS, 6-minute walking test</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy : change from baseline to 3 &amp; 6 months of Sesta-mibi scan</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>: change from baseline to 3 &amp; 6 months of symptom-limited exercise time,exercise-induced ischemia &amp; METs on Sesta-mibi scan</measure>
  </secondary_outcome>
  <enrollment>24</enrollment>
  <condition>Coronary Artery Disease</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VesCell (TM)-Autologous EPCs/Angiogenic Cell Precursors</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with chronic stable angina on maximal medical therapy and an occluded&#xD;
             coronary artery supplying an ischemic viable myocardial region as shown on Sestamibi&#xD;
             scan. On coronary angiography, the occluded coronary artery must have a patent&#xD;
             proximal segment of at least 30 mm with at least one side branch to enable the&#xD;
             injection of the EPC if the vessel remains occluded despite the attempted angioplasty&#xD;
             efforts.&#xD;
&#xD;
          -  Patients are not candidates for or are not willing to undergo CABG surgery.&#xD;
&#xD;
          -  Age 18 to 80 years&#xD;
&#xD;
          -  Male or non-pregnant, non-lactating female&#xD;
&#xD;
          -  Ejection fraction &gt;35% on Sestamibi&#xD;
&#xD;
          -  Sestamibi scan (myocardial perfusion) during exercise or dipyridamole, demonstrating&#xD;
             regional reversible ischemia in an area relating to the occluded coronary artery.&#xD;
&#xD;
          -  Informed consent obtained and consent form signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients not satisfying the coronary angiography and Sestamibi criteria&#xD;
&#xD;
          -  Patient who received blood transfusions during the previous 4 weeks (to exclude the&#xD;
             potential of non-autologous EPCs in the harvested blood).&#xD;
&#xD;
          -  Inability to communicate (that may interfere with the clinical evaluation&#xD;
&#xD;
          -  Myocardial infarction during the preceding 3 months&#xD;
&#xD;
          -  Significant valvular disease or after valve replacement&#xD;
&#xD;
          -  After heart transplantation&#xD;
&#xD;
          -  Cardiomyopathy&#xD;
&#xD;
          -  Renal failure (creatinine 10% above the upper limit according to the hospital&#xD;
             normograms)&#xD;
&#xD;
          -  Hepatic failure&#xD;
&#xD;
          -  Anemia (lower than 11mg/dl.hemoglobin for female and lower than 12 mg/dl for male)&#xD;
&#xD;
          -  Abnormal coagulation tests normal [platelets, PT (INR), PTT]&#xD;
&#xD;
          -  Stroke within the preceding 3 years&#xD;
&#xD;
          -  Malignancy within the preceding 3 years&#xD;
&#xD;
          -  Concurrent chronic or acute infectious disease&#xD;
&#xD;
          -  Severe concurrent medical disease (e.g., septicemia, HIV-1,2/HBV/HCV infections,&#xD;
             insulin-dependent diabetes mellitus, systemic lupus erythematosus, multiple sclerosis,&#xD;
             amyotrophic lateral sclerosis)&#xD;
&#xD;
          -  Chronic immunomodulating or cytotoxic drugs treatment&#xD;
&#xD;
          -  Patients who have rectal temp. above 38.40C for 2 consecutive days&#xD;
&#xD;
          -  Patient unlikely to be available for follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Damras Tresukosol, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of Cardiac Catherlization unit,Division of Cardiology,Department of Medicine,Faculty of Medicine Siriraj Hospital,Mahidol University ,BKK,Thailand</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. Valentin Fulga</name>
      <address>
        <city>Kiryat Weizmann Science Park, Nes Zionna</city>
        <zip>74140</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2006</verification_date>
  <study_first_submitted>October 5, 2006</study_first_submitted>
  <study_first_submitted_qc>October 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2006</study_first_posted>
  <last_update_submitted>October 19, 2006</last_update_submitted>
  <last_update_submitted_qc>October 19, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2006</last_update_posted>
  <keyword>Coronary Artery disease with chronic stable angina</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

